SARS-CoV-2 infection can cause severe pneumonia (COVID-19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS-CoV-2 viraemia with fatal outcome in patients after rituximab therapy.
No takes yet. Share an insight, caveat, or question.
Tepasse et al. (2020) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: